SHR-8068；Adebrelimab
Phase 2Monoclonal antibody
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-8068；Adebrelimab is one of 41 small molecule programs targeting Advanced Renal Cell Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 3
EMRELIS
AbbViePhase 3
Consolidative Therapy
SSun Yat-sen University
Phase 3
SHR-8068；Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-8068；Adebrelimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details